Novartis to use ParXware to manage Phase III trial

Boston, MA, November 16, 2000 -- Perceptive Informatics, Inc. (Perceptive), a newly established subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced today that Novartis, a key client, will use ParXwareT in its clinical trials management and data analysis. ParXware is a web-enabled tool that provides critical metrics that facilitate trial management, as well as sophisticated data analysis tools, including powerful data visualization and drill down capability. ParXware is a component of ParXnet, Perceptive's comprehensive web portal that brings enterprise-wide information to the desktop for a variety of applications supporting the drug development and launch processes. The functionality includes clinical trials management, data warehousing and mining, overall portfolio management, knowledge management, and training.

Novartis initially will use ParXware for a large transplantation trial, involving 50 sites and 600 patients throughout 14 countries. "Having real-time access to key trial metrics and data, as well as the ability to analyze the data as it becomes available, will allow us to make faster decisions regarding ongoing development programs," said Dr. James Shannon, Head of Clinical Research and Development at Novartis.

"Novartis has long been a valued partner of PAREXEL and we are pleased to extend this collaboration to our technology offerings," said Josef von Rickenbach, CEO of PAREXEL International Corporation.

Mark A. Goldberg, M.D., President of Perceptive, added, "We believe ParXware will bring real benefits to Novartis' clinical development processes and we look forward to working closely with them to maximize the value provided by this and other web-based tools."

Perceptive Informatics, Inc provides a variety of web-based portal solutions designed to accelerate and enhance the clinical development and product launch processes, as well as a range of voice and data systems. It also offers one of the industry's leading medical imaging service supporting the use of advanced imaging techniques in clinical development. The company has a growing operations and development staff of over 125 employees in four locations in North America and Europe.

PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that accelerate time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. The Company's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 45 locations throughout 29 countries around the world, and has approximately 4,200 employees.

This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended September 30, 2000.